Deferasirox induces mesenchymal-epithelial transition in crocidolite-induced mesothelial carcinogenesis in rats

Cancer Prevention Research

Volumn 6, Issue 11, 2013, Pages 1222-1230

  Nagai, Hirotaka ^a   Okazaki, Yasumasa ^a   Chew, Shan Hwu ^a   Misawa, Nobuaki ^a   Yasui, Hiroyuki ^b   Toyokuni, Shinya ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CROCIDOLITE; DEFERASIROX; IRON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HISTOPATHOLOGY; IRON STORAGE; LUNG CARCINOGENESIS; MAXIMUM TOLERATED DOSE; NONHUMAN; PHLEBOTOMY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SPLEEN; TISSUE LEVEL;

ANIMALS; ASBESTOS, CROCIDOLITE; BENZOATES; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; IRON; IRON CHELATING AGENTS; MALE; MESOTHELIOMA; PHLEBOTOMY; RATS; SPLEEN; TRIAZOLES;

EID: 84887970737     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0244     Document Type: Article

References (32)

1. Roggli VL, Oury TD, Sporn TA, editors. Pathology of asbestos-associated diseases. 2nd ed. New York: Springer-Verlag; 2004.
2. Pass HI, Vogelzang NJ, Carbone M, editors. Malignant mesothelioma; advances in pathogenesis, diagnosis, and translational therapies. New York: Springer Science+Business Media Inc.; 2005.
3. Toyokuni S. Mechanisms of asbestos-induced carcinogenesis. Nagoya J Med Sci 2009;71:1-10.
4. IARC, WHO. Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite). IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens; part C: arsenic, metals, fibres, and dusts. Lyon, France: IARC, WHO; 2012. p. 219-309.
5. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005;49(Suppl 1):S3-8. (Pubitemid 40798835)
6. Editorial. Editorials this week: asbestos scandal. Nature 2010;468:868.
7. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603. (Pubitemid 41434638)
8. Jakobsen JN, Sorensen JB. Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother Pharmacol 2011;68:1-15.
9. Donaldson K, Murphy FA, Duffin R, Poland CA. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010;7:5.
10. Nagai H, Toyokuni S. Biopersistent fiber-induced inflammation and carcinogenesis: lessons learned from asbestos toward safety of fibrous nanomaterials. Arch Biochem Biophys 2010;502:1-7.
11. Nagai H, Toyokuni S. Differences and similarities between carbon nanotubes and asbestos fibers during mesothelial carcinogenesis: shedding light on fiber entry mechanism. Cancer Sci 2012;103:1378-90.
12. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 2009;100:9-16.
13. Nagai H, Ishihara T, Lee WH, Ohara H, Okazaki Y, Okawa K, et al. Asbestos surface provides a niche for oxidative modification. Cancer Sci 2011;102:2118-25.
14. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047-52.
15. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553-66. (Pubitemid 26097272)
16. Kato J, Kobune M, Kohgo Y, Sugawara N, Hisai H, Nakamura T, et al. Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in Long-Evans Cinnamon rats. J Clin Invest 1996;98:923-9. (Pubitemid 26293309)
17. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007;42:830-6. (Pubitemid 47617461)
18. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002. (Pubitemid 352019800)
19. Jiang L, Nagai H, Ohara H, Hara S, Tachibana M, Hirano S, et al. Characteristics and modifying factors of asbestos-induced oxidative DNA damage. Cancer Sci 2008;99:2142-51.
20. Jiang L, Akatsuka S, Nagai H, Chew SH, Ohara H, Okazaki Y, et al. Iron overload signature in chrysotile-induced malignant mesothelioma. J Pathol 2012;228:366-77.
21. Okada S, Hamazaki S, Toyokuni S, Midorikawa O. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. Br J Cancer 1989;60:708-11. (Pubitemid 19275735)
22. Hu Q, Akatsuka S, Yamashita Y, Ohara H, Nagai H, Okazaki Y, et al. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest 2010;90:360-73.
23. Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther 2007;29:2154-66. (Pubitemid 350138570)
24. Guariglia R, Martorelli MC, Villani O, Pietrantuono G, Mansueto G, D'Auria F, et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leukemia Res 2011;35:566-70.
25. Nagai H, Okazaki Y, Chew SH, Misawa N, Yamashita Y, Akatsuka S, et al. Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis. Proc Natl Acad Sci U S A 2011;108:E1330-8.
26. Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007;6:235-9. (Pubitemid 46767631)
27. Dubourg L, Laurain C, Ranchin B, Pondarre C, Hadj-Aissa A, Sigaudo-Roussel D, et al. Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Pediatr Nephrol 2012;27:2115-22.
28. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
29. Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA. Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer 2006;51:53-9. (Pubitemid 43088624)
30. Okazaki Y, Nagai H, Chew SH, Jiang L, Funahashi S, Tsujimura T, et al. CD146 and insulin-like growth factor 2 mRNA-binding protein 3 predict prognosis of asbestos-induced rat mesothelioma. Cancer Sci 2013;104:989-95.
31. Messa E, Carturan S, Maffe C, Pautasso M, Bracco E, Roetto A, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010;95:1308-16.
32. Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009;1:303-14.